Dialysis Hyperphosphatemia Therapeutics Market Global Report 2026

The dialysis hyperphosphatemia therapeutics market size has grown rapidly in recent years. It will grow from $4.47 billion in 2025 to $4.95 billion in 2026 at a compound annual growth rate (CAGR) of 10.8%. The growth during the historic period was driven by increasing prevalence of chronic kidney disease and kidney failure, rising global dialysis patient population, growing awareness of phosphate management complications, increasing adoption of phosphate binder medications, and expanding healthcare infrastructure for renal care services.

The dialysis hyperphosphatemia therapeutics market size is expected to see rapid growth in the next few years. It will grow to $7.34 billion in 2030 at a compound annual growth rate (CAGR) of 10.3%. The growth during the forecast period is attributed to growing development of novel first-in-class phosphate control therapies, rising demand for personalized renal disease management, increasing focus on combination therapy approaches, growing adoption of home dialysis treatment models, and expanding investment in advanced kidney disease research. Major trends in the forecast period include increasing development of advanced phosphate binder therapies, growing adoption of personalized hyperphosphatemia treatment approaches, rising focus on improved patient compliance with oral therapeutics, increasing research on novel mechanisms for phosphate control, and growing demand for safer and more effective dialysis support therapies.

The increasing prevalence of chronic kidney disease is expected to drive the growth of the dialysis hyperphosphatemia therapeutics market in the coming years. Kidney disease refers to a group of conditions in which the kidneys are damaged or unable to effectively filter waste, excess fluids, and toxins from the blood, resulting in impaired body function and potential health complications. The rising prevalence of chronic kidney disease is primarily attributed to the increasing incidence of diabetes, which can progressively damage the kidneys by impairing their ability to filter waste products and excess fluids from the bloodstream. Dialysis hyperphosphatemia therapeutics support kidney disease management by controlling elevated phosphate levels in patients undergoing dialysis, thereby reducing complications such as bone disorders, cardiovascular damage, and mineral imbalances. For example, in June 2023, according to Kidney Research UK, a UK-based charitable organization dedicated to research and advocacy for improving the understanding, prevention, and treatment of kidney diseases, approximately 7.19 million people in the UK were living with chronic kidney disease in 2023, representing more than 10% of the country's population, with this number projected to increase to 7.61 million by 2033. Therefore, the increasing prevalence of chronic kidney disease is driving the growth of the dialysis hyperphosphatemia therapeutics market.

Major companies operating in the dialysis hyperphosphatemia therapeutics market are focusing on developing innovative therapies, including phosphate absorption inhibitors, to improve serum phosphorus control and reduce pill burden for dialysis patients. Phosphate absorption inhibitors are advanced therapies that decrease phosphate uptake in the intestine by blocking phosphate transport pathways instead of binding phosphate within the gastrointestinal tract like conventional phosphate binders. For example, in October 2023, Ardelyx Inc., a US-based biopharmaceutical company, received approval from the U.S. Food and Drug Administration (FDA) for XPHOZAH, the first phosphate absorption inhibitor indicated for adults with chronic kidney disease (CKD) on dialysis who have an inadequate response to phosphate binder therapy. XPHOZAH employs a differentiated mechanism of action that blocks paracellular phosphate absorption in the intestine and is administered as a single tablet twice daily, helping lower serum phosphorus levels while reducing the daily pill burden compared to conventional phosphate binder treatments.

In March 2026, Alebund Pharmaceuticals (Jiangsu) Limited, a China-based renal-focused biopharmaceutical company, entered into a partnership with R1 Therapeutics Inc. to advance the development of therapies for kidney diseases. Through this partnership, Alebund Pharmaceuticals (Jiangsu) Limited aims to expand its renal therapeutics pipeline and strengthen strategic collaboration in kidney care innovation, while R1 Therapeutics Inc. seeks to accelerate clinical-stage development through funding support and partnerships with leading dialysis providers and global investors. R1 Therapeutics Inc. is a US-based clinical-stage biotechnology company specializing in the development of therapies for kidney diseases.

Major companies operating in the dialysis hyperphosphatemia therapeutics market are Akebia Therapeutics Inc., Alebund Pharmaceuticals (Jiangsu) Limited, Alkem Laboratories Ltd., Amgen Inc., Amneal Pharmaceuticals Inc., Ardelyx Inc., Aurobindo Pharma Limited, Biocon Limited, Cipla Limited, Vifor Pharma Management Ltd., Dr. Reddy’s Laboratories Ltd., Emcure Pharmaceuticals Limited, Intas Pharmaceuticals Ltd., Kissei Pharmaceutical Co. Ltd., Kyowa Kirin Co. Ltd., Lupin Limited, OPKO Health Inc., R1 Therapeutics, Sanofi, Sanwa Kagaku Kenkyusho Co. Ltd., Strides Pharma Science Limited, Sun Pharmaceutical Industries Ltd., Takeda Pharmaceutical Company Limited, Unicycive Therapeutics Inc., Zydus Lifesciences Limited.

North America was the dominating region in the dialysis hyperphosphatemia therapeutics market in 2025. Asia-Pacific is expected to be the rapidly growing region in the forecast period. The regions covered in the dialysis hyperphosphatemia therapeutics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the dialysis hyperphosphatemia therapeutics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

This product will be delivered within 3-5 business days.